article thumbnail

Designing antibodies to think before they bind

Drug Target Review

Meet Jhong-Jhe (JJ) You JJ joined AP Biosciences in 2013 as the company’s first employee, leading the development of the Omni-Mab human antibody phage display library and building a robust cell-based assay platform for screening and isolating functional antibodies for immunotherapy.

article thumbnail

Time for change: non-human primates in drug research

Drug Target Review

7 This initiative forms part of a broader effort to modernise drug development and align regulatory expectations with emerging new approach methodologies (NAMs), including human cell-based assays, artificial intelligence models and organ-on-chip platforms.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gamcemetinib

New Drug Approvals

nM) and cell based assays ( EC 50 =89 nM). Gamcemetinib CAS 1887069-10-4 CC-99677 , OS2IR8TV1O Molecular Weight 469.94 Gamcemetinib is extracted from patent WO2020236636, compound 1.

article thumbnail

Cell Viability Assays – Are your cells happy? | BMG Labtech

BMG Labtech

In measuring cell viability, membrane integrity is a key indicator, as only viable cells with intact membranes are counted as living. Next to cell viability assays, cell-based assays can also be employed to analyse other cellular events like cytotoxicity, reactive oxygen species (ROS) production or cell metabolism.

article thumbnail

A covalent compound selectively inhibits RNA demethylase ALKBH5 rather than FTO

Covalent Modifiers

Herein, we used a targeted covalent inhibition strategy and identified a covalent inhibitor, TD19, which selectively inhibits ALKBH5 compared with FTO demethylase in protein-based and tumor cell-based assays. TD19 irreversibly modifies the residues C100 and C267, preventing ALKBH5 from binding to m6A-containing RNA.

RNA 157
article thumbnail

Generation and characterization of mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of IL-23 [Drug Discovery and Translational Medicine]

ASPET

Mirikizumab effectively inhibits the interaction of IL-23 with its receptor, and potently blocks IL-23-induced IL-17 production in cell-based assays while preserving the function of IL-12. In both local and systemic in vivo mouse models, mirikizumab blocked IL-23-induced keratin mRNA or IL-17 production, respectively.

article thumbnail

The Novel GlycoPEGylated FGF21 Analog Pegozafermin Activates Human FGF Receptors and Improves Metabolic and Liver Outcomes in Diabetic Monkeys and Healthy Human Volunteers [Drug Discovery and Translational Medicine]

ASPET

In cell-based assays, pegozafermin had a similar receptor engagement profile as native FGF21, with approximately 8-fold higher potency at FGF receptor 1 (FGFR1).